Cipla Limited
CIPLA
Pozycja w akcjach
#1816
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Cena akcji
$14.61
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$11.80B
Zmiana (1 dzień)
-0.12%
Zmiana (1 rok)
-21.66%
Kraj
IN
Handel Cipla Limited (CIPLA)
Kategoria
Healthcare
Zyski dla Cipla Limited (CIPLA)
Zyski w Jun 2026 TTM: $499.57M
Według najnowszych raportów finansowych Cipla Limited, obecny zysk firmy wynosi $499.57M. W roku 2024 firma osiągnęła zysk w wysokości $683.63M, wzrost w porównaniu do zysku z roku 2023, który wynosił $491.08M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Cipla Limited od 2004 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $499.57M | -37.16% |
| 2025 | $794.95M | 16.28% |
| 2024 | $683.63M | 39.21% |
| 2023 | $491.08M | 7.11% |
| 2022 | $458.50M | 2.41% |
| 2021 | $447.69M | 58.29% |
| 2020 | $282.83M | -4.75% |
| 2019 | $296.94M | 16.00% |
| 2018 | $255.98M | 36.61% |
| 2017 | $187.39M | -27.61% |
| 2016 | $258.87M | -0.84% |
| 2015 | $261.05M | -3.94% |
| 2014 | $271.76M | -29.32% |
| 2013 | $384.50M | 34.66% |
| 2012 | $285.52M | 9.46% |
| 2011 | $260.85M | -11.65% |
| 2010 | $295.26M | 67.39% |
| 2009 | $176.40M | -15.76% |
| 2008 | $209.41M | 12.35% |
| 2007 | $186.39M | 16.95% |
| 2006 | $159.38M | 35.23% |
| 2005 | $117.85M | 26.61% |
| 2004 | $93.09M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 253.21% |
IN
|
